The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://blakejzou679300.timeblog.net/74815378/glp-3-retatrutide-a-comparative-analysis